137 related articles for article (PubMed ID: 38063980)
21. Prostate cancer mortality in the Finnish randomized screening trial.
Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
[TBL] [Abstract][Full Text] [Related]
22. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men.
Siltari A; Murtola TJ; Kausz J; Talala K; Taari K; Tammela TL; Auvinen A
Acta Oncol; 2023 Dec; 62(12):1898-1904. PubMed ID: 37971326
[TBL] [Abstract][Full Text] [Related]
23. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial.
Carlsson SV; Arnsrud Godtman R; Pihl CG; Vickers A; Lilja H; Hugosson J; Månsson M
Eur Urol; 2023 Feb; 83(2):103-109. PubMed ID: 36334968
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use.
Murtola TJ; Virkku A; Talala K; Stenman UH; Taari K; Tammela TLJ; Auvinen A
J Urol; 2017 Aug; 198(2):305-309. PubMed ID: 28216328
[TBL] [Abstract][Full Text] [Related]
25. The Finnish prostate cancer screening trial: analyses on the screening failures.
Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
Int J Cancer; 2015 May; 136(10):2437-43. PubMed ID: 25359457
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
Neupane S; Steyerberg E; Raitanen J; Talala K; Pylväläinen J; Taari K; Tammela TL; Auvinen A
Int J Urol; 2018 Mar; 25(3):270-276. PubMed ID: 29224236
[TBL] [Abstract][Full Text] [Related]
27. Population-based case-control study of PSA and DRE screening on prostate cancer mortality.
Bergstralh EJ; Roberts RO; Farmer SA; Slezak JM; Lieber MM; Jacobsen SJ
Urology; 2007 Nov; 70(5):936-41. PubMed ID: 18068451
[TBL] [Abstract][Full Text] [Related]
28. Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
Beckmann K; Kinsella N; Olsson H; Wallerstedt Lantz A; Nordstrom T; Aly M; Adolfsson J; Eklund M; Van Hemelrijck M
BMC Urol; 2019 Aug; 19(1):73. PubMed ID: 31383015
[TBL] [Abstract][Full Text] [Related]
29. Second round results of the Finnish population-based prostate cancer screening trial.
Mäkinen T; Tammela TL; Stenman UH; Määttänen L; Aro J; Juusela H; Martikainen P; Hakama M; Auvinen A
Clin Cancer Res; 2004 Apr; 10(7):2231-6. PubMed ID: 15073097
[TBL] [Abstract][Full Text] [Related]
30. Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data.
Booth N; Rissanen P; Tammela TLJ; Taari K; Talala K; Auvinen A
Eur J Cancer; 2018 Apr; 93():108-118. PubMed ID: 29501976
[TBL] [Abstract][Full Text] [Related]
31. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
de Vos II; Remmers S; Hogenhout R; Roobol MJ;
Eur Urol; 2024 Jan; 85(1):74-81. PubMed ID: 37919190
[TBL] [Abstract][Full Text] [Related]
32. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH; Hugosson J; Carlsson S; Tammela T; Määttänen L; Auvinen A; Kwiatkowski M; Recker F; Roobol MJ
Eur Urol; 2012 Nov; 62(5):745-52. PubMed ID: 22704366
[TBL] [Abstract][Full Text] [Related]
33. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
34. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.
Hugosson J; Carlsson S; Aus G; Bergdahl S; Khatami A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
Lancet Oncol; 2010 Aug; 11(8):725-32. PubMed ID: 20598634
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Bokhorst LP; Bangma CH; van Leenders GJ; Lous JJ; Moss SM; Schröder FH; Roobol MJ
Eur Urol; 2014 Feb; 65(2):329-36. PubMed ID: 23954085
[TBL] [Abstract][Full Text] [Related]
36. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.
Roobol MJ; Kranse R; Bangma CH; van Leenders AG; Blijenberg BG; van Schaik RH; Kirkels WJ; Otto SJ; van der Kwast TH; de Koning HJ; Schröder FH;
Eur Urol; 2013 Oct; 64(4):530-9. PubMed ID: 23759326
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
Roobol MJ; Kerkhof M; Schröder FH; Cuzick J; Sasieni P; Hakama M; Stenman UH; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis L; Recker F; Berenguer A; Ruutu M; Kujala P; Bangma CH; Aus G; Tammela TL; Villers A; Rebillard X; Moss SM; de Koning HJ; Hugosson J; Auvinen A
Eur Urol; 2009 Oct; 56(4):584-91. PubMed ID: 19660851
[TBL] [Abstract][Full Text] [Related]
38. Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer.
Lindberg A; Talala K; Kujala P; Stenman UH; Taari K; Kilpeläinen TP; Tammela TL; Auvinen A
Int J Cancer; 2019 Aug; 145(3):632-638. PubMed ID: 30653262
[TBL] [Abstract][Full Text] [Related]
39. Towards an optimal interval for prostate cancer screening.
van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
[TBL] [Abstract][Full Text] [Related]
40. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.
Määttänen L; Hakama M; Tammela TL; Ruutu M; Ala-Opas M; Juusela H; Martikainen P; Stenman UH; Auvinen A
Br J Cancer; 2007 Jan; 96(1):56-60. PubMed ID: 17213825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]